Ambulatory blood pressure monitoring can detect forms of hypertension that may go unnoticed during one-time checks at the doctor’s office. Some people have elevated blood pressure in healthcare settings and normal blood pressure at home, or vice versa. Other people only have high blood pressure when asleep. 

Biobeat’s device assesses blood pressure by measuring the time it takes for a pressure wave from a heartbeat to move between two sites. The measurement, called the pulse wave transit time, is one of several ways that researchers have tried to estimate blood pressure using cuffless devices. Biobeat received 510(k) clearance for its latest device in January 2025.

New Biobeat investors Ally Bridge Group, OrbiMed Advisors and Elevage Medical led a $50 million Series B investment to support expanded commercialization in the U.S. An unnamed strategic investor also joined the round. Biobeat will use the money to try to establish its cuffless device as a go-to option for monitoring blood pressure in the 100 million hypertensive patients in the U.S.